[go: up one dir, main page]

WO2007046962A3 - Cell lines harboring hepatitis virus and methods for using thereof - Google Patents

Cell lines harboring hepatitis virus and methods for using thereof Download PDF

Info

Publication number
WO2007046962A3
WO2007046962A3 PCT/US2006/034442 US2006034442W WO2007046962A3 WO 2007046962 A3 WO2007046962 A3 WO 2007046962A3 US 2006034442 W US2006034442 W US 2006034442W WO 2007046962 A3 WO2007046962 A3 WO 2007046962A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
methods
infected
relates
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034442
Other languages
French (fr)
Other versions
WO2007046962A2 (en
Inventor
David Oldach
Scott Heyward
Paul Silber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
University of Maryland College Park
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of WO2007046962A2 publication Critical patent/WO2007046962A2/en
Publication of WO2007046962A3 publication Critical patent/WO2007046962A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to cryopreserved primary hepatocytes infected with hepatitis C virus (HCV), which, when thawed and cultured, are capable of being infected with and releasing infectious HCV. The present invention also relates to methods of producing primary cryopreserved hepatocytes infected with hepatitis C virus (HCV), wherein the HCV-infected primary hepatocytes are capable of releasing new infectious HCV. The present invention also relates to methods of using HCV-infected primary hepatocytes to screen drug candidates for their ability to affect HCV infection and/or replication. The invention also relates to methods of producing infectious HCV in vitro and methods of using this infectious HCV such as, but not limited to, preparing vaccines directed towards HCV, its receptor or virus-receptor intermediate states.
PCT/US2006/034442 2005-09-02 2006-09-05 Cell lines harboring hepatitis virus and methods for using thereof Ceased WO2007046962A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59616205P 2005-09-02 2005-09-02
US60/596,162 2005-09-02

Publications (2)

Publication Number Publication Date
WO2007046962A2 WO2007046962A2 (en) 2007-04-26
WO2007046962A3 true WO2007046962A3 (en) 2007-10-25

Family

ID=37962969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034442 Ceased WO2007046962A2 (en) 2005-09-02 2006-09-05 Cell lines harboring hepatitis virus and methods for using thereof

Country Status (1)

Country Link
WO (1) WO2007046962A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208291B2 (en) 2015-07-23 2019-02-19 Grifols, S.A. Method for generating high-titer hepatitis E virus stocks and titration assay for hepatitis E virus

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149817A (en) * 2008-09-12 2011-08-10 弗·哈夫曼-拉罗切有限公司 Production of infectious hepatitis c virus particles in cell culture
KR102015933B1 (en) * 2012-04-08 2019-08-29 인벤트프라이즈 엘엘씨 Systems and methods of virus propagation in cell culture for vaccine manufacture
HK1207884A1 (en) 2012-08-31 2016-02-12 The Governors Of The University Of Alberta Methods for producing cells having a phenotype of a primary human hepatocytes and compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
WO2005054450A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
WO2005054450A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208291B2 (en) 2015-07-23 2019-02-19 Grifols, S.A. Method for generating high-titer hepatitis E virus stocks and titration assay for hepatitis E virus

Also Published As

Publication number Publication date
WO2007046962A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2010107739A3 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
TW200720285A (en) Nucleoside compounds for treating viral infections
WO2006075993A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
WO2011041713A3 (en) Piperazinyl antiviral agents
WO2007052163A3 (en) Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2010021681A3 (en) Compositions and methods for treatment of viral diseases
EP2234977A4 (en) Viral polymerase inhibitors
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
CL2009000305A1 (en) Compounds derived from 2-aryl-substituted-1-benzofuran-3-carboxamide, ns5b polymerase inhibitors; pharmaceutical composition; and its use in the treatment of a disease caused by the hepatitis c virus (hcv).
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2007084413A3 (en) Methods for treating hepatitis c
WO2011015656A3 (en) Composition for treating hbv infection
WO2010047830A3 (en) Agents for hcv treatment
SI2125889T1 (en) Human antibodies against hepatitis c virus (hcv) uses thereof
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2009080806A3 (en) Modified influenza virus
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2006131936A3 (en) Hepatitis c virus vaccine
WO2006069064A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2007046962A3 (en) Cell lines harboring hepatitis virus and methods for using thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06814135

Country of ref document: EP

Kind code of ref document: A2